NAD+ is a coenzyme, not a peptide, sold as IV drips, injection kits and nasal sprays at the same clinics that sell peptides. A 2026 systematic review found no eligible outcomes trial of direct NAD+ for anti-aging or wellness use. The one randomized, placebo-controlled human trial found tested a cardiac population, not wellness or addiction, and the addiction-treatment claim widely marketed rests on one uncontrolled 50-person pilot. A controlled comparison found IV NAD+ causes significantly more gastrointestinal and cardiac-adjacent symptoms than IV nicotinamide riboside, and an FDA warning letter ties a contaminated NAD+ lot to a Class I recall.
Ask about NAD+
Research snapshot
| Peptide category | Coenzyme (dinucleotide), not a peptide, included because it is marketed at the same wellness clinics as peptides |
| Primary research interest | Cellular energy metabolism and DNA-damage repair support; marketed for anti-aging, addiction/withdrawal, and general wellness |
| Highest available evidence | One published randomized, placebo-controlled human trial (cardiac population); a 2026 systematic review found no eligible outcomes trial for anti-aging or wellness use |
| Human research available | Limited: one RCT in heart failure; the addiction claim rests on a single uncontrolled 50-person pilot; no controlled trial for cognition, fatigue, or general wellness by direct administration |
| Development status | Not in pharmaceutical development for direct administration; sold only as a compounded product |
| Regulatory status | Not FDA-approved for any indication or route; active FDA warning letter and Class I recall tied to an endotoxin-contaminated NAD+ lot (January 2026) |
Technical identity
| Primary name | NAD+ (Nicotinamide Adenine Dinucleotide) |
| Alternative names | NAD; nicotinamide adenine dinucleotide; Nadide (INN); Coenzyme I (Chinese pharmacopeia name); “NAD+ drip”, “NAD IV therapy”, “NAD+ booster” (community names) |
| Peptide sequence | Not applicable: NAD+ is a dinucleotide coenzyme, not a peptide |
| Amino-acid length | Not applicable |
| Molecular formula | Not independently re-verified in this research pass |
| Molecular weight | Not independently re-verified in this research pass |
| CAS Registry Number | Not independently re-verified in this research pass |
| PubChem CID | Not independently re-verified in this research pass |
| UNII | Not established |
| DrugBank ID | Not established |
| Chemical modifications | Not applicable: endogenous coenzyme, no modifications; distinct from precursors NMN and NR and from the reduced form NADH, which are separate molecules with their own literature |
| Peptide class | Not applicable: dinucleotide coenzyme built from an adenine nucleotide and a nicotinamide nucleotide |
| Primary biological target | Substrate for sirtuin enzymes (SIRT1-7), PARP enzymes, and CD38; central to glycolysis, the citric acid cycle, fatty-acid oxidation, and the mitochondrial electron transport chain |
| Developer or originator | Not applicable: naturally occurring metabolite present in every human cell |
| Development status | No FDA-approved drug product exists; everything sold clinically is compounded from bulk powder |
What it is
NAD+, nicotinamide adenine dinucleotide, is not a peptide. It is a dinucleotide coenzyme built from an adenine nucleotide and a nicotinamide nucleotide, and it is a normal metabolite present in every human cell. It appears on this site because it is marketed and sold the same way peptides are, at the same wellness clinics and IV bars, not because it is chemically related to them.
This entry covers direct, exogenous administration of NAD+ itself: intravenous drips, intramuscular or subcutaneous injection, and intranasal spray. It does not cover the oral precursor compounds NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside, sold as Niagen or Tru Niagen), which the body converts into NAD+ through one or two enzymatic steps, or nicotinamide and niacin, further upstream vitamin-form precursors; those are a separate topic with their own, in places much larger, literature. NADH, the reduced form of NAD+, is likewise a distinct molecule, studied separately and by a different route (orally, for chronic fatigue). Vendor and consumer material routinely blurs all of this together under the phrase “NAD booster,” and an “NAD+ injection” sold at a clinic may in fact contain NAD+ itself or may be an NMN or NR product marketed under the same loose language; which one a person was actually given determines which evidence base, if any, applies. NAD+ also appears under its Chinese pharmacopeia name, “Coenzyme I,” in some trial registrations; that is the same molecule, not a different substance.
Mechanism
The underlying biochemistry is well established. NAD+ accepts electrons, becoming NADH, during glycolysis, the citric acid cycle and fatty-acid oxidation, and NADH is re-oxidized back to NAD+ at the mitochondrial electron transport chain to drive ATP synthesis, a cycle continuous in every human cell. NAD+ is also the substrate sirtuin enzymes (SIRT1-7) consume in DNA-damage signaling and metabolic regulation, the substrate PARP enzymes consume during DNA-damage repair, and the substrate CD38 degrades; CD38 activity rises with age and inflammation and is one of the most-cited explanations for why tissue NAD+ falls with age.
A large preclinical literature, mostly using oral precursors rather than NAD+ itself, reports that restoring NAD+ improves mitochondrial function and metabolic markers as animals age. The step from that finding to “raising NAD+ in humans changes aging or disease outcomes” is a hypothesis under study, not an established fact, and a 2026 review states directly that intravenous NAD+ administration “is less well characterized and lacks robust clinical validation” (Pandolfi 2026). A more consequential open question is whether NAD+ given by IV or intranasal route ever reaches the inside of a human cell intact: NAD+ is a relatively large, charged dinucleotide, and whether it crosses cell membranes as itself, is broken down extracellularly with its components re-taken-up as smaller precursors, or acts partly through cell-surface signaling, is not resolved in the literature reviewed. That gap is the premise the entire IV NAD+ industry depends on, and it is addressed further below.
Potential benefits and research applications
Heart failure, the one demonstrated benefit, and a narrow one
What is being investigated: whether IV NAD+ improves cardiac function in ischemic cardiomyopathy heart failure when added to standard therapy. How the effect might occur: by supporting mitochondrial energy metabolism and electron transport chain function in stressed heart tissue. Evidence: a randomized, placebo-controlled trial of 180 patients found ejection fraction rose to 45.44 percent with NAD+ against 42.44 percent with placebo at one month. Strength: has been shown in one registered human trial. Limitation: the effect was numerically small, no secondary endpoint reached significance on its own, the trial used a Chinese registry rather than ClinicalTrials.gov, and the authors themselves call for validation in larger, multicenter trials before this should be read as established.
Addiction and withdrawal, the claim driving the most consumer demand with the least evidence
What is being investigated: whether IV NAD+ reduces craving, anxiety and withdrawal symptoms in substance use disorder. How the effect might occur: no specific mechanism has been established; proposed effects on neurotransmitter and energy metabolism remain speculative for this use. Evidence: one uncontrolled, unblinded, open-label pilot of 50 people reported large improvements in craving, anxiety and depression scores. Strength: has been reported anecdotally in a single uncontrolled pilot; has not been established. Limitation: no randomized controlled trial of IV NAD+ for opioid or alcohol withdrawal has been located, and the pilot combined NAD+ with enkephalinase-inhibition infusions, so even its own uncontrolled result cannot isolate NAD+’s contribution.
General wellness, anti-aging and cognitive support, the marketing claims with the thinnest record
What is being investigated: whether raising circulating or tissue NAD+ improves energy, cognition, fatigue or exercise performance. How the effect might occur: through NAD+’s established roles as a substrate for sirtuin and PARP enzymes involved in metabolism and DNA-damage repair. Evidence: a large preclinical literature using oral precursor compounds, not NAD+ itself, reports metabolic benefits in aging animals. Strength: has not been established for direct NAD+ administration in humans by any route. Limitation: a 2026 systematic review of 113 studies found no eligible outcomes trial evaluating IV or intramuscular NAD+ itself for anti-aging or wellness indications, and whether NAD+ given by IV or intranasal route even reaches the inside of a human cell intact remains an open, unresolved question in the literature.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Ischemic cardiomyopathy heart failure (Yu 2025) | Intravenous | 10 mg/day | Once daily | 7 days, assessed at 1 and 6 months | Published human clinical trial (randomized, placebo-controlled, n=180) |
| Infusion tolerability comparison (Reyna 2026) | Intravenous | 500 mg/day | Once daily | 4 consecutive days, 30-day follow-up | Published human research (retrospective, non-randomized, real-world EMR review) |
| Substance use disorder / withdrawal (Blum 2022) | Intravenous, combined with enkephalinase-inhibition infusions | Not detailed in the source reviewed | Not detailed in the source reviewed | Not detailed in the source reviewed | Published human research (uncontrolled, unblinded, open-label pilot, n=50) |
| General wellness / anti-aging IV infusion (community/clinic) | Intravenous | Roughly 250 mg to 1,000 mg per session | Single sessions or 3-10 day loading protocol | Loading protocol followed by weekly to monthly maintenance infusions | Vendor/clinic reported: well above the only controlled-source figure (500 mg over 4 days) and far above the 10 mg/day dose used in the one positive randomized trial; no trial has tested this loading/maintenance pattern for any outcome |
| Self-administered wellness injection (community) | Subcutaneous or intramuscular | Tens of milligrams to roughly 200 mg per injection | Varies by product | Ongoing, often alongside precursor products | Vendor/community reported |
| Intranasal spray (community) | Intranasal | Low milligram amounts per metered spray | Varies by product | Ongoing | Vendor reported: no human clinical data on intranasal NAD+ absorption or effect in a wellness context has been located |
What the human trials found
Direct NAD+ administration has been studied far less than its marketing footprint suggests. A 2026 PRISMA-guided review, searching January 2010 through October 2025, found 113 eligible human and rodent NAD-related intervention studies and stated: “No eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness indications” (Gallagher & Emmanuel 2026). That is close to a definitive statement of the gap between what is marketed and what has been tested.
The one real exception is a randomized, placebo-controlled trial in a cardiac population, not a wellness one. A single-center Chinese trial (registry ChiCTR2200059169, not ClinicalTrials.gov) randomized 180 adults with ischemic cardiomyopathy and reduced ejection fraction to IV NAD+ 10 mg per day for 7 days, added to guideline-directed heart failure therapy, or placebo. Ejection fraction at one month rose to 45.44 percent with NAD+ against 42.44 percent with placebo, significant but numerically small; no secondary endpoint reached significance on its own, and the authors call for validation in larger, multicenter trials (Yu 2025). This trial has nothing to do with addiction treatment, cognition, fatigue or anti-aging, and generalizing its result to those uses is not supported by the trial itself.
A separate retrospective comparison, drawn from records at a commercial IV-therapy clinic chain, is the clearest documented source for what is often described anecdotally as IV NAD+’s infusion discomfort. Adults received four consecutive days of either 500 mg IV NAD+ or 500 mg IV nicotinamide riboside, with 30-day follow-up. The NAD+ group reported moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during infusion, versus only minor tingling and mild cramping with NR; NAD+ infusions also took roughly two and a half times longer, averaging 97 minutes against 37 for NR, because the rate had to be slowed for tolerability. Standard liver, kidney and inflammatory labs did not change significantly in either group; HDL cholesterol fell significantly with NAD+ specifically (Reyna 2026). This is real, quantified evidence, but from one clinic network’s retrospective records, not a controlled trial.
The addiction and withdrawal claim, which drives much of the consumer demand for IV NAD+, rests on the thinnest evidence found. The most substantial source is a peer-reviewed but uncontrolled, unblinded, open-label pilot of 50 people with treatment-resistant substance use disorder, given IV NAD+ with enkephalinase-inhibition infusions, reporting large improvements in self-rated craving, anxiety and depression, and clean urine screens partway through treatment; the authors call for larger randomized, placebo-controlled trials (Blum 2022). Beyond that pilot sits a 2014 conference poster on a retrospective review of 60 people given IV NAD+ alongside vitamins and amino acids, not NAD+ alone, and a described 2017 follow-up whose own source calls it an unpublished manuscript still in preparation. No randomized controlled trial of IV NAD+ for opioid or alcohol withdrawal has been located.
For cognition, fatigue and exercise performance by the direct route, the record is close to empty. No controlled trial of IV, intramuscular or intranasal NAD+ for cognition has been located; the trials in that space all used an oral precursor instead. The one placebo-controlled fatigue trial retrieved used oral NADH, a different molecule taken by a different route, in 86 adults over two months, and found no significant improvement on fatigue intensity, function or quality of life, its primary outcomes; only a small reduction in anxiety score and post-exercise heart rate reached significance (Alegre 2010). No interventional trial of direct NAD+ and exercise capacity was located, and the one relevant intranasal-NAD+ study tested olfactory recovery in mice, with the human component confined to cultured cells in vitro.
Safety
Two safety findings are documented rather than anecdotal, and point in different directions. The first is the infusion-tolerability pattern above: IV NAD+ was associated with moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during administration, in a controlled comparison against IV nicotinamide riboside, requiring roughly two and a half times the infusion time to keep symptoms manageable (Reyna 2026); standard hepatic, renal and inflammatory labs did not move significantly over 30 days in that dataset. The second is a documented manufacturing failure, not a property of the molecule. An FDA warning letter to a compounding outsourcing facility, dated 20 January 2026, names NAD+ specifically, reporting a lot found to contain excessive bacterial endotoxin, measured at 3,360 EU/mL, after which three patients experienced hypotension and fever, and a voluntary recall covering 56 sterile-product lots, with the endotoxin-contaminated NAD+ lot elevated to Class I, the classification reserved for a reasonable probability of serious harm or death. This is evidence that at least one compounder’s sterile-manufacturing process failed, not that NAD+ itself is inherently dangerous when properly compounded, and the two should not be collapsed together. No published protocol for cardiac pre-screening, infusion-rate titration or post-infusion monitoring was located, because there is no approved label to set one; no long-term controlled safety data for repeated IV NAD+ administration exists, and the longest controlled human exposure documented is seven days of dosing plus 30-day follow-up.
Regulatory status
NAD+ is not an FDA-approved drug for any indication, by any route. There is no NDA, ANDA or BLA covering it, no FDA label, no approved dose and no FDA-reviewed efficacy or safety data as a drug product. Everything sold clinically as IV NAD+ therapy, NAD+ injections or NAD+ nasal spray is compounded from bulk powder, not dispensed under an approved application, and compounded drugs are by definition not FDA-reviewed for safety or effectiveness. NAD+’s status on the FDA list of substances eligible for compounding from bulk remains unresolved years after nomination, and the warning letter above treats a compounder’s use of NAD+ as making an unapproved new drug. NAD+ does not appear on the current World Anti-Doping Agency Prohibited List, unlike the growth-hormone-releasing peptides discussed elsewhere on this site; as an endogenous metabolite present in every human cell, it sits in a different regulatory category, a factual contrast, not an endorsement of unsupervised IV use.
What circulates
Clinic-administered IV NAD+ is commonly marketed in per-session amounts described as roughly 250 mg to 1,000 mg, often front-loaded as a multi-day protocol and followed by periodic maintenance infusions. The one controlled dataset above used 500 mg per day for four days, the single figure in this range with a named, published source; the rest is a general market pattern, not sourced to any named vendor or dated. At-home injection kits are marketed at smaller amounts, tens to a couple hundred milligrams, often alongside precursor products rather than NAD+ alone. Nasal sprays are marketed at low-milligram per-spray amounts; no human clinical data on intranasal NAD+ absorption or effect in a wellness context has been located, and the only intranasal-NAD+ study found was the mouse and cell-culture olfactory-repair study above, not the kind of use these products market.
Measured against what has actually been studied, this range sits well above its own only controlled-source figure (500 mg over four days), and the marketed loading and maintenance schedule has no published trial testing that pattern for any outcome. The heart-failure trial’s 10 mg-per-day, seven-day protocol, the only randomized human dose with a positive result, is far below what wellness clinics typically infuse, and was tested under medical supervision in a cardiac population, not a wellness-seeking one. NAD+ is also frequently sold combined with glutathione, vitamins and amino acids, or with low-dose naltrexone or metformin in some registered trial designs, meaning a clinic’s reported patient experience is often the effect of a multi-ingredient protocol rather than NAD+ alone, mirroring the addiction pilot above. Marketing material typically cites general biochemical roles such as cellular energy or DNA repair without citing the thin human trial evidence in this entry, and without disclosing that the product is an unapproved compounded drug or that a documented tolerability profile and a 2026 endotoxin-related recall exist for this category.
What the record gets wrong
The central problem with IV and intranasal NAD+ is not that it has been shown not to work; it is that the basic premise behind giving it this way has not been shown to hold. Whether NAD+ delivered into the bloodstream or nasal passage raises NAD+ inside the cells it is meant to reach, rather than being broken down outside the cell with only smaller components taken back up, is open and contested, and no human study located here directly answered it by measuring intracellular NAD+ before and after infusion. Every downstream claim about cellular energy, DNA repair or anti-aging effect depends on that unresolved step.
Layered on that gap, the two claims driving the most consumer interest, anti-aging or wellness and addiction or withdrawal treatment, are the two with the least direct evidence: a 2026 systematic review found no eligible outcomes trial of IV or intramuscular NAD+ for either use, and the addiction claim rests on one uncontrolled 50-person pilot and unpublished conference material, not a randomized controlled trial. The one real randomized, placebo-controlled trial of direct NAD+ in humans found a modest ejection-fraction benefit in a cardiac population, at a fraction of the dose typically infused at wellness clinics, and its own authors call it preliminary. A separate, published comparison confirms IV NAD+ causes significantly more gastrointestinal and cardiac-adjacent symptoms than an IV precursor and takes substantially longer to infuse. And the FDA has documented an NAD+ lot contaminated with bacterial endotoxin severe enough to cause patient harm and trigger a Class I recall, inside a compounding supply chain with no FDA-approved manufacturing standard, because no FDA-approved NAD+ product exists.
Frequently asked questions
What is NAD+?
NAD+ is a naturally occurring coenzyme present in every human cell, sold as IV drips, injection kits and nasal sprays at wellness clinics. It is not a peptide and has no FDA approval for any use.
How does it work?
NAD+ is a substrate for enzymes involved in cellular energy production and DNA-damage repair. Whether giving it by IV or nasal route actually raises NAD+ inside human cells, rather than being broken down before it gets there, is an open, unresolved question.
What dosage has been studied?
The one randomized trial with a positive result used 10 mg IV per day for 7 days in heart failure patients. A separate retrospective tolerability comparison used 500 mg IV per day for 4 days. No dose-ranging study of IV NAD+ exists for any outcome.
What dosage commonly circulates online?
Wellness clinics commonly market 250 mg to 1,000 mg per IV session, often as a multi-day loading protocol. That range sits well above the only controlled-source figure (500 mg over four days) and far above the 10 mg dose used in the one positive randomized trial.
Has it been studied in humans?
Yes, but far less than its marketing footprint suggests. A 2026 systematic review of 113 studies found no eligible outcomes trial of IV or intramuscular NAD+ for anti-aging or wellness use. The one randomized, placebo-controlled trial found is in cardiac patients, not wellness or addiction.
Does it help with addiction or withdrawal?
That claim, which drives much of the consumer demand for IV NAD+, rests on one uncontrolled, unblinded, open-label pilot of 50 people. No randomized controlled trial of IV NAD+ for opioid or alcohol withdrawal has been located.
What side effects have been reported?
A controlled comparison found IV NAD+ caused significantly more gastrointestinal symptoms, increased heart rate and chest pressure than IV nicotinamide riboside, and took roughly 2.6 times as long to infuse. Separately, an FDA warning letter documented an NAD+ lot contaminated with bacterial endotoxin severe enough to cause patient harm and trigger a Class I recall.
Is it approved?
No. NAD+ has no FDA approval for any indication or route. Everything sold as IV NAD+ therapy is compounded from bulk powder outside FDA-reviewed manufacturing standards.
What remains unknown?
Whether NAD+ given by IV or nasal route actually reaches the inside of human cells intact; whether it treats addiction or withdrawal better than supportive care; whether it affects cognition, fatigue or exercise performance; and what dose, if any, is appropriate for any indication.
Bottom line
NAD+ is a real, essential cellular coenzyme, but direct administration of it, by IV, injection or nasal spray, has been studied far less than its marketing suggests. The one randomized, placebo-controlled human trial found a modest benefit in heart failure at a fraction of the dose wellness clinics typically infuse. The addiction-treatment and general anti-aging claims driving most consumer interest rest on one uncontrolled pilot and a systematic review that found no eligible outcomes trial at all. A controlled comparison documented real infusion-tolerability problems, and an FDA warning letter ties a contaminated lot to a Class I recall, in a compounding supply chain with no FDA-approved manufacturing standard.
Reported amounts and the evidence behind them: NAD+ dosage by route.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| General wellness, anti-aging IV infusion | Intravenous | Roughly 250 mg to 1,000 mg per session | Single sessions or 3-10 day loading protocol | Loading protocol followed by weekly to monthly maintenance infusions |
| Self-administered wellness injection | Subcutaneous or intramuscular | Tens of milligrams to roughly 200 mg per injection | Varies by product | Ongoing, often alongside precursor products |
| Convenience/at-home alternative to IV | Intranasal spray | Low milligram amounts per metered spray | Varies by product | Ongoing |
What circulates for IV NAD+ clusters around 250 mg to 1,000 mg per session, often front-loaded as a multi-day protocol and followed by periodic maintenance infusions, with smaller self-injected amounts and low-milligram nasal sprays marketed as more convenient alternatives. None of this is sourced to a named vendor and none of it is dated; it is a general market pattern, not a verified live listing, and should be treated as such. Measured against what has actually been studied, this range sits well above the only figure in it with a controlled human source, 500 mg over four consecutive days from a retrospective tolerability comparison, and far above the 10 mg-per-day, seven-day protocol used in the one randomized trial with a positive result, which was tested in a cardiac population under medical supervision, not a wellness-seeking one. No trial has tested the multi-day loading and ongoing maintenance pattern that is actually marketed, for any outcome, and NAD+ is frequently sold as part of a multi-ingredient blend, so a clinic's reported patient experience is often the effect of that combination rather than NAD+ given alone.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- Gallagher K, Emmanuel A. PRISMA-guided systematic review, January 2010-October 2025, of 113 eligible human and rodent NAD-related intervention studies. States that no eligible outcomes trial evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness indications. Human and animal, review. PMID 41655607
- Pandolfi et al. 2026. States that intravenous NAD+ administration is less well characterized and lacks robust clinical validation, and that responses are nonlinear and depend on dose, age, metabolic state and route of administration. Review. PMID 42489969
- Yu et al. Single-center, randomized, placebo-controlled trial (ChiCTR2200059169), n=180 adults with ischemic cardiomyopathy, LVEF ≤45%. IV NAD+ 10 mg/day for 7 days versus placebo, added to guideline-directed therapy. LVEF at 1 month 45.44% vs 42.44%, P=0.024; secondary endpoints (NT-proBNP, 6-month MACCE, hospitalization, NYHA improvement) not independently significant. Human RCT. PMID 40954388
- Reyna et al. Retrospective real-world EMR review (RestoreLabs/Restore Hyperwellness) comparing 4 consecutive days of 500 mg IV NAD+ to 500 mg IV nicotinamide riboside, 30-day follow-up. IV NAD+ associated with moderate to severe GI symptoms, increased heart rate and chest pressure during infusion, versus minor tingling/cramping with NR; NAD+ infusions averaged 97 minutes versus 37 minutes for NR. No significant change in ALT, AST, hsCRP, BUN/creatinine or TSH in either group; HDL-C fell significantly in the NAD+ group. Human, retrospective, non-randomized. PMID 41704678
- Blum et al. Uncontrolled, open-label pilot, n=50 treatment-resistant substance use disorder patients, IV NAD+ combined with enkephalinase-inhibition infusions. Reported improvements in craving, anxiety and depression scores and negative urine screens on 40 patients midway through treatment; no control or comparator arm, no blinding, no randomization. Authors call for larger randomized, placebo-controlled trials. Human, uncontrolled pilot. DOI 10.2174/2666082218666220527114427
- Alegre et al. Double-blind, placebo-controlled trial, n=86 (77 completers) chronic fatigue syndrome patients, oral NADH 20 mg/day versus placebo for 2 months. No significant difference on fatigue intensity, functional performance or quality of life, the primary outcomes; small significant reductions in anxiety score and post-exercise heart rate only. Oral NADH, a different molecule from NAD+, taken by a different route. Human RCT, negative on primary endpoint. PMID 20447621
- US Food and Drug Administration warning letter to GenoGenix LLC (Boca Raton, FL), 20 January 2026, naming NAD+ specifically as not appearing on the 503B bulk drug substances list, citing adulteration, unapproved-new-drug and inadequate-labeling provisions. Documents an NAD+ lot with bacterial endotoxin at 3,360 EU/mL and three patients with hypotension and fever following administration, and a voluntary recall initiated 30 July 2025 covering 56 product lots, one classified FDA Class I. Regulatory, web-sourced; recommended for direct re-verification against fda.gov before further reliance. FDA warning letter 718739
Compare NAD+ with related compounds
Research area: Longevity and mitochondrial.